312 related articles for article (PubMed ID: 32495965)
21. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
22. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY; Salem JE; Cohen JV; Chandra S; Menzer C; Ye F; Zhao S; Das S; Beckermann KE; Ha L; Rathmell WK; Ancell KK; Balko JM; Bowman C; Davis EJ; Chism DD; Horn L; Long GV; Carlino MS; Lebrun-Vignes B; Eroglu Z; Hassel JC; Menzies AM; Sosman JA; Sullivan RJ; Moslehi JJ; Johnson DB
JAMA Oncol; 2018 Dec; 4(12):1721-1728. PubMed ID: 30242316
[TBL] [Abstract][Full Text] [Related]
23. Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study.
Haeuser L; Marchese M; Cone EB; Noldus J; Bayliss G; Kilbridge KL; Trinh QD
Nephrol Dial Transplant; 2022 Jun; 37(7):1310-1316. PubMed ID: 34028534
[TBL] [Abstract][Full Text] [Related]
24. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
Wang H; Yang H; Zhou X; Zhang X
Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
[TBL] [Abstract][Full Text] [Related]
25. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors.
Cutroneo P; Ingrasciotta Y; Isgrò V; Rullo EV; Berretta M; Fiorica F; Trifirò G; Guarneri C
Dermatol Ther; 2021 Mar; 34(2):e14830. PubMed ID: 33527643
[TBL] [Abstract][Full Text] [Related]
26. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system.
Moore DC; Elmes JB; Arnall JR; Strassels SA; Patel JN
Int Immunopharmacol; 2022 Sep; 110():109015. PubMed ID: 35803131
[TBL] [Abstract][Full Text] [Related]
27. The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database.
Tang Q; Han Y; Song M; Peng J; Zhang M; Ren X; Sun H
Medicine (Baltimore); 2024 Mar; 103(13):e37587. PubMed ID: 38552079
[TBL] [Abstract][Full Text] [Related]
28. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
29. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years.
Ruggiero R; Balzano N; Di Napoli R; Fraenza F; Pentella C; Riccardi C; Donniacuo M; Tesorone M; Danesi R; Del Re M; Rossi F; Capuano A
Front Immunol; 2023; 14():1134436. PubMed ID: 37006303
[TBL] [Abstract][Full Text] [Related]
30. Guillain-Barré syndrome in patients treated with immune checkpoint inhibitors.
Fan Q; Hu Y; Wang X; Zhao B
J Neurol; 2021 Jun; 268(6):2169-2174. PubMed ID: 33475824
[TBL] [Abstract][Full Text] [Related]
31. Do immune checkpoint inhibitors share the same pharmacological feature in the risk of cardiac arrhythmias?
Mascolo A; Sportiello L; Rafaniello C; Donniacuo M; Ruggiero D; Scisciola L; Barbieri M; Rossi F; Paolisso G; Capuano A
Biomed Pharmacother; 2023 Aug; 164():114912. PubMed ID: 37210896
[TBL] [Abstract][Full Text] [Related]
32. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
33. Nephrotoxicity of Immune Checkpoint Inhibitors: A Disproportionality Analysis from 2013 to 2020.
Qu J; Ding Y; Jiang K; Hao J; Li Y; Zhang A; Li Z; Qi G; Xu Z; Liu X; Ma J; Bi K; Li Z
Tohoku J Exp Med; 2021 Aug; 254(4):275-282. PubMed ID: 34433731
[TBL] [Abstract][Full Text] [Related]
34. Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data.
Chen G; Qin Y; Fan QQ; Zhao B; Mei D; Li XM
Cancer Med; 2020 Sep; 9(18):6576-6585. PubMed ID: 32720449
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wu X
J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance.
Ebinama U; Sheshadri A; Anand K; Swaminathan I
J Immunother Precis Oncol; 2023 Nov; 6(4):177-184. PubMed ID: 38143955
[TBL] [Abstract][Full Text] [Related]
37. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
[TBL] [Abstract][Full Text] [Related]
38. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
[TBL] [Abstract][Full Text] [Related]
39. Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014-2021.
Xu Z; Qi G; Liu X; Li Z; Zhang A; Ma J; Li Z
PLoS One; 2023; 18(3):e0281983. PubMed ID: 36881599
[TBL] [Abstract][Full Text] [Related]
40. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system.
Li C; Li Z; Sun Q; Xiang Y; Liu A
Expert Opin Drug Saf; 2024 Jun; 23(6):777-784. PubMed ID: 37622438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]